texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Dallas Cancer Research & Clinical Trials

Texas Oncology cancer centers in Dallas participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Dallas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current clinical trials.

Our cancer researchers in the Dallas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Dallas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Dallas area and talk to your doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Bladder Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Brain Cancer

Title: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) View

Indication: Brain Cancer

Location: Texas Oncology-McKinney

Title: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) View

Indication: Brain Cancer

Location: Texas Oncology-Plano West

Breast Cancer

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: A randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: Ph1b Abemaciclib + SOC in mBC View

Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b Abemaciclib + SOC in mBC View

Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b Abemaciclib + SOC in mBC View

Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Mesquite

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Title: Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Mesquite

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Cervical Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Colon Cancer

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Endometrial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Esophageal Cancer

Title: Nivo/Ipi v Nivo/5FU v 5FU 1L Sq Esoph View

Description: CA209648: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 648)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo/Ipi v Nivo/5FU v 5FU 1L Sq Esoph View

Description: CA209648: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 648)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo/Ipi v Nivo/5FU v 5FU 1L Sq Esoph View

Description: CA209648: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 648)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Essential Thrombocythemia

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Mesquite

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Fallopian Tube Cancer

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Gastric Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

General Oncology

Title: A Randomized, Double-blind Phase 3 Study of Relatlimab (BMS-986016) Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma View

Indication: General Oncology

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Randomized, Double-blind Phase 3 Study of Relatlimab (BMS-986016) Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma View

Indication: General Oncology

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Randomized, Double-blind Phase 3 Study of Relatlimab (BMS-986016) Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma View

Indication: General Oncology

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Graft vs Host Disease

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

GU

Title: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors View

Indication: GU

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors View

Indication: GU

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors View

Indication: GU

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Head and Neck Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Hematologic

Title: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Title: Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab View

Indication: Hematologic

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Title: A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Mesquite

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Mesquite

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Plano East

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Plano West

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Sherman

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Kidney Cancer

Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) View

Indication: Kidney Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Kidney Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Kidney Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Kidney Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Leukemia

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Mesquite

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Plano East

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Sherman

Phase: IV

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Liver Cancer

Title: Pembro post Sorafenib HCC View

Description: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Pembro post Sorafenib HCC View

Description: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Pembro post Sorafenib HCC View

Description: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Lung Cancer

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Title: An Expanded Access Protocol for Lorlatinib for Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: An Expanded Access Protocol for Lorlatinib for Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: An Expanded Access Protocol for Lorlatinib for Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III/IV

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Lymphomas

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Sherman

Phase: III

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Denton South

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Mesquite

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Plano West

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Sherman

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: I/II

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Melanoma

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Plano West

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Mesothelioma

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Myelodysplastic Syndrome

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Myelofibrosis

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Mesquite

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Myelomas

Title: PREAMBLE - Observational in 1L & R/R MM View

Description: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE)

Indication: Myelomas

Location: Texas Oncology-Sherman

Title: Observational INSIGHT MM study View

Description: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001)

Indication: Myelomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen

Indication: Myelomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Neuroendocrine Tumors

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Ovarian Cancer

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Pancreas

Title: A Phase IIa, Multicenter, Open-label, Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer (the COMBAT study) View

Indication: Pancreas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase IIa, Multicenter, Open-label, Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer (the COMBAT study) View

Indication: Pancreas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase IIa, Multicenter, Open-label, Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer (the COMBAT study) View

Indication: Pancreas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Pancreatic Cancer

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Penile Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Peritoneal Cancer

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Peritoneal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Peritoneal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Peritoneal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA:(A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Indication: Peritoneal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Prostate Cancer

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Mesquite

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: PHIII IGRT/SBRTvsIGRT/HypoIMRT IntProst View

Description: Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005)

Indication: Prostate Cancer

Location: Texas Oncology-Plano West

Phase: III

Rectal Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Renal Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Sherman

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Sarcoma

Title: A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolimide as a Second-Line Regimen for Ewing’s Sarcoma View

Indication: Sarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Skin Cancer

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Solid Tumors

Title: Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Mesquite

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Sherman

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: IV

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Testicular Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Thymomas

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Thyroid Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Urothelial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Mesquite

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Sherman

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Wichita Falls Cancer Center

Phase: II

Title: Ph2 Rucaparib mUC View

Description: ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (CO-338-085)

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Uterine Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Vaginal Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Phase IIa, Multicenter, Open-label, Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer (the COMBAT study) View

Indication: Pancreas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Kidney Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors View

Indication: GU

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: An Expanded Access Protocol for Lorlatinib for Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Randomized, Double-blind Phase 3 Study of Relatlimab (BMS-986016) Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma View

Indication: General Oncology

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b Abemaciclib + SOC in mBC View

Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo/Ipi v Nivo/5FU v 5FU 1L Sq Esoph View

Description: CA209648: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 648)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Pembro post Sorafenib HCC View

Description: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Peritoneal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase IIa, Multicenter, Open-label, Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer (the COMBAT study) View

Indication: Pancreas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Kidney Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors View

Indication: GU

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: An Expanded Access Protocol for Lorlatinib for Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Randomized, Double-blind Phase 3 Study of Relatlimab (BMS-986016) Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma View

Indication: General Oncology

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b Abemaciclib + SOC in mBC View

Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo/Ipi v Nivo/5FU v 5FU 1L Sq Esoph View

Description: CA209648: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 648)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Pembro post Sorafenib HCC View

Description: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Peritoneal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase IIa, Multicenter, Open-label, Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Subjects with Metastatic Pancreatic Cancer (the COMBAT study) View

Indication: Pancreas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (E7080-G000-307) View

Indication: Kidney Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Phase 1b Multicohort Study of Anetumab Ravtansine for Mesothelin-Positive Advanced Solid Tumors (Study No 15834) in multiple indications (NSCLC, Thymic cancer, Triple negative breast cancer, gastric cancer, cholangiocarcinoma and pancreatic cancer) View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Retrospective Chart Review to Evaluate the Clinical Outcomes of Breast Cancer Patients Treated with Xeloda and Radiation Therapy on the T0-0401 Clinical Trial at Texas Oncology - Sammons Cancer Center View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors View

Indication: GU

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: An Expanded Access Protocol for Lorlatinib for Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations View

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Randomized, Double-blind Phase 3 Study of Relatlimab (BMS-986016) Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma View

Indication: General Oncology

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors View

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b Abemaciclib + SOC in mBC View

Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1 SGN-LIV1A Metastatic BC View

Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Destiny1:Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo/Ipi v Nivo/5FU v 5FU 1L Sq Esoph View

Description: CA209648: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 648)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Pembro post Sorafenib HCC View

Description: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: An Open-Label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%) (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1 INCB050465 B-Cell (CITADEL-112) View

Description: INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Peritoneal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph 2/3 Nivo 1L mCRC View

Description: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CA209-9X8)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Nivo/Cab or Nivo/Ipi/Cab vs Sun mRCC View

Description: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CA209-9ER)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PhI/II PK Multi Tumor SubQ Nivo Mono View

Description: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy (CA2098KX)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Skin Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Phase 1/2a BMS-986253 + Nivo View

Description: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1b BGB-A317 + BGB-290 Adv Solid Tumor View

Description: A Phase 1/1b, Open Label, Multiple Dose, Dose Escalationand Expansion Study to Investigate the Safety,Pharmacokinetics and Antitumor Activity of theanti-PD-1 Monoclonal Antibody BGB-A317 inCombination with the PARP Inhibitor BGB-290 inSubjects with Advanced Solid Tumors

Indication: Vaginal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Texas Oncology-Denton South

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Title: Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Denton South

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Denton South

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Denton South

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Title: Ph2 Rucaparib mUC View

Description: ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (CO-338-085)

Indication: Urothelial Cancer

Location: Texas Oncology-Denton South

Phase: II

Texas Oncology-Flower Mound

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: IV

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: An Open-label Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Texas Oncology-McKinney

Title: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) View

Indication: Brain Cancer

Location: Texas Oncology-McKinney

Texas Oncology-Medical City Dallas Building C

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Title: A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III/IV

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Texas Oncology-Medical City Dallas Building D

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Title: A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III/IV

Title: STAR Ph2 Brigatinib ALK+ NSCLC View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolimide as a Second-Line Regimen for Ewing’s Sarcoma View

Indication: Sarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Texas Oncology-Medical City Dallas Radiation Oncology

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy View

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Sacituzumab Govitecan(SASSY) vs PC mTNBC View

Description: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (IMMU-132-05)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Participants with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Graft vs Host Disease

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Itacitinib GVHD (GRAVITAS309) View

Description: INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II